SubHero Banner

Orencia® (abatacept) – New orphan indication

On December 15, 2021, the FDA announced the approval of Bristol-Myers Squibb’s Orencia (abatacept), for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor (URD).

Download PDF